Core Insights - Psyched Wellness Ltd. has launched a new product called Calmer, which is a more potent version of its existing product Calm, offering twice the potency [1][2] - The company has also improved the flavor profile of Calm, reducing the mushroom taste while maintaining its potency [2] - A Black Friday promotion is currently being offered, providing a 40% discount on all products (excluding merchandise) until December 1, 2025 [2] Product Development - Calmer is developed based on feedback from monthly subscribers who requested a stronger version of Calm [2] - The company has concentrated its proprietary extract AME-1 without compromising the product's potency or consumer experience [2] Market Expansion - Psyched Wellness is actively expanding its route-to-market partnerships across Canada and the United States [2][3] - The company encourages interested distributors or retailers to reach out for potential partnerships [3] Company Background - Psyched Wellness Ltd. specializes in dietary supplements derived from the Amanita Muscaria mushroom, focusing on research and production of consumer packaged goods [4]

Core Insights - NooCube is a scientifically formulated nootropic supplement designed to enhance cognitive function, mental clarity, focus, and memory without the use of stimulants or harmful chemicals [6][10][20] - The supplement combines a unique blend of natural ingredients that work synergistically to support overall brain performance and protect against cognitive decline [7][12][13] Product Overview - NooCube is marketed as a "smart drug" or "brain productivity booster" aimed at improving cognitive abilities for individuals of all ages [5][6] - The formula includes ingredients such as Alpha GPC, Huperzine A, Bacopa Monnieri, and L-Theanine, which are known for their roles in enhancing neurotransmitter activity and protecting brain cells from oxidative stress [7][17][19] Benefits - Regular use of NooCube can lead to sharper concentration, quicker thinking, better recall, and reduced mental fatigue, making it particularly beneficial in fast-paced environments [8][24] - The supplement is designed to provide smooth, sustained mental energy without jitters or crashes, making it suitable for students, professionals, and entrepreneurs [8][14] Safety and Quality - NooCube emphasizes safety and transparency, using premium, non-GMO ingredients and undergoing strict quality testing to ensure purity and effectiveness [9][19] - Each ingredient is clinically tested for potency, ensuring users experience real cognitive benefits [19][22] Target Audience - NooCube is suitable for a wide range of users, including students looking to enhance learning, professionals needing sustained focus, and older adults aiming to support long-term brain health [44][45] - The product is positioned as a natural alternative for anyone seeking improved cognitive performance and mental energy [46][47] Usage Guidelines - For optimal results, NooCube should be taken consistently as part of a daily routine, with a recommended dosage of two capsules each morning [41][42] - Users may adjust the dosage up to four capsules per day based on cognitive needs, but exceeding this limit is not advised [42][43]

Core Insights - Zinzino has acquired 35% of Xion International Group to form a joint venture focused on algae production using bioreactors, aiming to secure a sustainable supply of omega-3 for its product BalanceOil+ [1][2][7] - The partnership with Xion, which has developed advanced photobioreactor technology for microalgae production, is expected to enhance Zinzino's product portfolio and brand protection [3][4][6] Financial Details - The acquisition cost Zinzino EUR 1.2 million, with EUR 0.7 million paid in cash and EUR 0.5 million settled through newly issued shares [5] Strategic Importance - This initiative is part of Zinzino's broader strategy to meet increasing global demand and expand its market presence while ensuring sustainable growth [2][6] - The collaboration with Xion will lead to the establishment of a new company, PhytoFerm, focused on producing omega-3 and other oils from algae, positioning Zinzino as a leader in sustainable nutritional solutions [7][8]

Financial Data and Key Metrics Changes - The company reported a record revenue of $34 million for Q3 2025, representing a 33% increase year over year, and a net income of $4.6 million compared to $1.9 million in the same period last year [5][14][17] - The cash position at the end of the quarter was $64.3 million with no debt [5][17] - Gross margin improved to 64.5%, up 100 basis points from 63.5% a year ago [16] Business Line Data and Key Metrics Changes - E-commerce business generated net sales of $19 million, a 29% increase year over year [5][14] - The distribution business saw a significant growth of 109% year over year, achieving $7 million in revenue [5][14] - Niagen ingredient business remained steady with revenue of $6.9 million, a 4% increase year over year [14] Market Data and Key Metrics Changes - The NAD market is expanding rapidly, with significant opportunities in skincare, cosmetics, food, beverage, and drug applications [8][10] - The company has onboarded over 1,000 wellness and healthcare clinics across the U.S. to offer the Niagen Plus product line [7][8] Company Strategy and Development Direction - The company aims to educate healthcare practitioners and consumers about Niagen as the most effective NAD booster available [6][8] - Plans to expand distribution of at-home injection kits via a telehealth platform are underway [7][34] - The company is considering establishing a standalone entity to pursue pharmaceutical applications of nicotinamide riboside, particularly for Parkinson's disease [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the updated full-year revenue growth guidance, revised from 22%-27% to 25%-30% year-over-year [18] - The company anticipates that gross margins will normalize on a quarterly basis moving forward, despite improvements year-over-year [16][19] - Management noted that the FDA's recent decision regarding NMN has not significantly impacted consumer purchasing behavior [36][37] Other Important Information - The company has over 40 peer-reviewed clinical studies supporting the efficacy of Niagen [9][12] - The National Advertising Division recently supported the company's position against false claims made by competitors regarding NAD products [10] Q&A Session Summary Question: What is the uptake looking like with the new partnership for IV? - Management indicated it is too early to provide feedback as the partnership just began reselling the material [24] Question: How does the "About NAD" site fit into the marketing funnel? - The site serves as an objective resource for information on NAD and is not part of the purchasing funnel [26] Question: Are at-home injection kits available in all clinics? - Currently, the kits are available in clinics, and the rollout for online purchasing is expected to take several months [33] Question: Has the FDA's announcement on NMN changed consumer purchasing behavior? - Management noted no significant changes in purchasing behavior since the announcement [36] Question: Will the company establish a standalone entity for pharmaceutical applications? - Management confirmed that establishing a standalone entity for pharmaceutical pursuits is likely, depending on study results and discussions with pharma companies [42]

Financial Performance - Total company net sales reached $34 million in Q3 2025, a 33% increase year-over-year[10] - Tru Niagen® net sales were $26 million in Q3 2025, up 44% year-over-year[10] - Gross margin improved to 64.5% in Q3 2025, a 100 basis points increase year-over-year[10] - Net income was $4.6 million, or $0.06 earnings per share, an increase of $2.7 million and $0.04 year-over-year[10] - Adjusted EBITDA reached $6.4 million, up $3.5 million year-over-year[10] - Cash provided from operations year-to-date was $12.8 million, with $64.3 million in cash and no debt[10] Sales Mix and Growth - Tru Niagen® net sales accounted for 77% of total net sales in Q3 2025, compared to 71% in Q3 2024[28] - Niagen®-related net sales remained at 97% of total net sales in both Q3 2025 and Q3 2024[28] - Year-to-date net sales reached $99.6 million, a 36% increase year-over-year[34] Outlook - The company reaffirmed its increased full-year 2025 net sales growth outlook to between 25% and 30%, driven by strong momentum in Tru Niagen® and Niagen® ingredients[10]

Egypt’s efforts to build up its economy and boost exports after a grueling crisis may be getting help from an unexpected industry: dietary supplements https://t.co/i1NLstrO74 ...

Core Points - ProPhase Labs Inc. will participate in a live Virtual Non-Deal Roadshow on September 4, 2025, to discuss its latest investor presentation [2][3] - The presentation will cover a general overview of the company, its crypto treasury strategy, significant liquidity events, and the cancellation of the Equity Line of Credit (ELOC) [3] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on healthcare innovation [5] - The company aims to revolutionize healthcare through Whole Genome Sequencing solutions and diagnostic developments, including a test for early detection of esophageal cancer [5] - ProPhase Labs is committed to executional excellence, smart diversification, and a synergistic omni-channel approach to health and wellness solutions [5]

Core Viewpoint - ProPhase Labs Inc. will present its second quarter 2025 financial results on August 13, 2025, at 2:00 pm EDT through a virtual conference call [1][2]. Group 1: Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on building a healthier world through innovation and actionable insights [4]. - The company is known for its Whole Genome Sequencing solutions and diagnostic developments, including a test for early detection of esophageal cancer [4]. - ProPhase Labs aims to develop, manufacture, and commercialize health and wellness solutions, emphasizing executional excellence and smart diversification [4]. Group 2: Event Details - A press release detailing the financial results will be issued prior to the virtual conference call [2]. - Stakeholders, investors, and individual followers are invited to register for the live event, with a replay available on the company's investor website afterward [2][3].

Financial Data and Key Metrics Changes - The company reported a record revenue of $31.1 million for Q2 2025, representing a 37% increase year over year, and a net income of $3.6 million compared to virtually breakeven a year ago [7][20]. - The cash position at the end of the quarter was $60.5 million with no debt [24]. - Gross margin improved to 65%, up from 60.2% a year ago, driven by lower cost inventory and higher e-commerce sales [22]. Business Line Data and Key Metrics Changes - E-commerce business generated $18.1 million in net sales, a 39% increase year over year [7][21]. - The food grade and pharmaceutical grade Niagen ingredient business grew 135% year over year, with revenue of $7.4 million [8][21]. - TRU NIAGEN revenue increased by 22% to $22.7 million, primarily driven by e-commerce revenues [21]. Market Data and Key Metrics Changes - The company is expanding its presence in wellness clinics, onboarding over 800 clinics nationwide to offer the Niagen Plus product line [8]. - The partnership with Watsons in Hong Kong is contributing to steady revenues, with plans for joint marketing efforts to grow brand presence [22]. Company Strategy and Development Direction - The company is focusing on expanding its Niagen Plus product line and exploring telehealth functionality on its website [9][8]. - A worldwide exclusive license agreement was signed with Haukeland University Hospital for the development of nicotinamide riboside as a potential therapy for Parkinson's disease [17]. - The company aims to maintain its position as the gold standard in NAD science and is committed to scientific innovation in the dietary supplement industry [14][20]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory and strategic goals, highlighting the strong demand for NAD products [19][20]. - The company raised its revenue growth expectation for the full year from 20%-25% to a range of 22%-27% year over year [27]. - Management noted ongoing scrutiny from California regarding outsourcing facility practices but remains optimistic about the partnership with Wells Pharmacy Network [9][10]. Other Important Information - The company has been featured in major media outlets and events, increasing awareness of its products [10][12]. - There is ongoing research into the effects of NAD supplementation on long COVID and fertility, with studies expected to be published soon [15][16][51]. Q&A Session Summary Question: Regarding the initiative for Parkinson's disease - Management indicated that if the NOPARC trial results are positive, they may pivot to nicotinamide riboside triacetate for FDA approval in the U.S. [30][32]. Question: Volume and pricing for NIAGEN IV in clinics - Management noted that while clinics are currently charging high prices for IV experiences, they believe prices need to come down to increase accessibility and volume [36][39]. Question: Steps for treating long COVID - The key milestone to watch is the publication of the Harvard study on NAD supplementation for long COVID, which could lead to a marketing campaign if results are positive [49][54].

Core Viewpoint - Safety Shot, Inc. has announced a registered direct offering and concurrent private placement to raise approximately $16.3 million, which will strengthen its balance sheet and support its operations following the recent merger approval with Yerbaé [1][3][5]. Group 1: Offering Details - The company is offering 22,993,492 shares of common stock at a price of $0.461 per share [1]. - In addition, warrants to purchase up to 45,986,984 shares of common stock have been issued, with a purchase price of $0.125 per warrant and an exercise price of $0.461 per share [2]. - The gross proceeds from both the registered direct offering and the private placement are expected to be around $16.3 million before fees and expenses [3]. Group 2: Strategic Importance - The CEO of Safety Shot emphasized that this financing is crucial for the company at a pivotal time, enhancing the balance sheet and providing necessary capital for daily operations and integration post-merger [5]. - The company aims to accelerate its commercial footprint and drive long-term value for shareholders with this capital infusion [5]. Group 3: Regulatory Information - The shares are being offered under a shelf registration statement filed with the SEC, which was declared effective on November 9, 2022 [4]. - A prospectus supplement detailing the terms of the offering will be filed with the SEC and made available on their website [4]. Group 4: Company Overview - Safety Shot, Inc. specializes in wellness and dietary supplements, with its flagship product, Sure Shot, designed to lower blood alcohol content while enhancing clarity and mood [7]. - The product is available for purchase on various online platforms, including Walmart and Amazon [7].